Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524690 | 0.86 | FABP5 (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL7401416 | 0.85 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL525363 | 0.82 | FABP5 (0.49) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL28126888 | 0.80 | FKBP1A (0.43) | FABP5FABP7 | |
| SCHEMBL17699252 | 0.79 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4789393 | 0.77 | LMNA (0.41) | — | |
| SCHEMBL12987541 | 0.76 | FABP5 (0.44) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL12987564 | 0.76 | FABP5 (0.44) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601031 | 0.75 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL12987567 | 0.75 | KMT2A (0.42) | FABP5FABP7KMT2AEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254092-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-11975081-B2 | Bifunctional chelators and conjugates | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11964948-B2 | Bifunctional chelators and conjugates | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240082438-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240051928-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9040531-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| EP-2427451-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BioLab Corporation (JP) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128685-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368262-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | FABP5 1359/4885FABP7 697/4885KMT2A 3392/4885 |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | FABP5 1359/4885FABP7 697/4885KMT2A 3392/4885 |
| US-20240254092-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | FABP5 2172/4885FABP7 1451/4885KMT2A 1003/4885 |
| US-11964948-B2 | Bifunctional chelators and conjugates | FOLH1, PAICS, TAP2 | FABP5 2172/4885FABP7 1451/4885KMT2A 1003/4885 |
| US-20240051928-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | FABP5 2172/4885FABP7 1451/4885KMT2A 1003/4885 |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | FABP5 1359/4885FABP7 697/4885KMT2A 3392/4885 |
| US-11975081-B2 | Bifunctional chelators and conjugates | FOLH1, PAICS, TAP2 | FABP5 2172/4885FABP7 1451/4885KMT2A 1003/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | FABP5 1359/4885FABP7 697/4885KMT2A 3392/4885 |
| US-20240082438-A1 | BIFUNCTIONAL CHELATORS AND CONJUGATES | FOLH1, PAICS, TAP2 | FABP5 2172/4885FABP7 1451/4885KMT2A 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.